34 hasil untuk "Hamza Hashmi"
Menampilkan 1–20 · 0,36 detik · RSS
-
Artikel Jurnal
Therapeutic Roles of Antibody Drug Conjugates (ADCs) in Relapsed/Refractory Lymphomas
Relapsed or refractory lymphoma is commonly treated with combination chemoimmunotherapy and cellular immunotherapy. Modest response rates and associated toxicities are obstacles to achieving durable remission using traditional cytotoxic chemotherapy, especially in frail patients with advanced…
-
Artikel Jurnal
Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma
Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment landscape of relapsed/refractory multiple myeloma. The current Food and Drug Administration approved CAR T cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel both target B cell maturation antigen (BCMA)…
-
Artikel Jurnal
Primary Effusion Lymphoma without an Effusion: A Rare Case of Solid Extracavitary Variant of Primary Effusion Lymphoma in an HIV-Positive Patient
Primary effusion lymphoma (PEL) is a unique form of non-Hodgkin lymphoma, usually seen in severely immunocompromised, HIV-positive patients. PEL is related to human herpesvirus-8 (HHV-8) infection, and it usually presents as a lymphomatous body cavity effusion in the absence of a solid tumor mass…
-
Artikel Jurnal
Effectiveness, Safety, and Cost Implications of Outpatient Autologous Hematopoietic Stem Cell Transplant for Multiple Myeloma
Background and objective: Autologous hematopoietic stem cell transplant (aHCT) has become standard care for patients with multiple myeloma (MM). Outpatient aHCT with high-dose melphalan conditioning has reduced costs and length of hospital stay. This study aimed to highlight the effectiveness…
-
Artikel Jurnal
A Rare Case of Erdheim-Chester Disease (Non-Langerhans Cell Histiocytosis) with Concurrent Langerhans Cell Histiocytosis: A Diagnostic and Therapeutic Challenge
Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocyte disorder most commonly characterized by multifocal osteosclerotic lesions of the long bones demonstrating sheets of foamy histiocyte infiltrates on biopsy with or without histiocytic infiltration of extraskeletal tissues. ECD…
-
Artikel Jurnal
Evaluating the Impact of Enhanced Recovery After Surgery (ERAS) Protocols on Postoperative Morbidity and Hospital Stay
Background: Enhanced Recovery after Surgery (ERAS) protocols are the scientifically-supported perioperative guidelines aimed at optimizing the recovery, minimizing the complications, as well as the hospitalization. The objective of this study was to determine the impact of ERAS measures on…
-
Artikel Jurnal
“Fast but not so furious”: A condensed step‐up dosing schedule of teclistamab for relapsed/refractory multiple myeloma
Abstract Teclistamab is a B‐cell maturation antigen (BCMA)‐directed bispecific T‐cell engager approved for relapsed‐refractory multiple myeloma (RRMM). Cytokine release syndrome (CRS) and Immune effector cell‐associated neurotoxicity syndrome (ICANS) are well‐documented treatment ‐related adverse…
-
Artikel Jurnal
Twice-daily intravenous bolus tacrolimus infusion: A safe and effective regimen for graft-versus-host disease prophylaxis
Objective/Background: Among patients undergoing allogeneic hematopoietic cell transplant, continuous intravenous (IV) tacrolimus infusion is frequently used for graft-versus-host disease (GvHD) prophylaxis. Twice-daily intermittent IV tacrolimus dosing may confer safety and convenience benefits…
-
Artikel Jurnal Teks lengkap
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
PURPOSE: Idecabtagene vicleucel (ide-cel) is an autologous B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy approved for relapsed/refractory multiple myeloma (RRMM) on the basis of the phase II pivotal KarMMa trial, which demonstrated best overall and ≥ complete response…
-
Artikel Jurnal
A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma
Abstract While initial trials led to the accelerated approval of belantamab mafodotin, a BCMA-directed antibody-drug conjugate, confirmatory trials failed to establish benefit from this therapy for patients with relapsed refractory multiple myeloma (RRMM), eventually leading to its withdrawal from…
-
Artikel Jurnal
Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy
Abstract The presence of extramedullary disease (EMD) has been associated with poor outcomes in patients with relapsed-refractory multiple myeloma (RRMM). Herein, we report the outcomes of RRMM patients who were treated with standard-of-care (SOC) chimeric antigen receptor (CAR) T-cell therapy and…
-
Artikel Jurnal
Talquetamab in heavily pretreated patients with multiple myeloma, including BCMA-refractory
Abstract: Talquetamab is a G protein–coupled receptor class C group 5 member D–targeting bispecific T-cell engager approved for patients with relapsed multiple myeloma based on the MonumenTAL-1 trial. In this retrospective study of 68 patients, we evaluated safety and efficacy of talquetamab in a…
-
Artikel Jurnal
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma
Abstract While CAR T has shown superior efficacy in earlier line of therapy [1, 2] for functionally high-risk multiple myeloma (FHRMM), outcomes with its use in later lines (3+) for FHR disease remain unknown. We describe a single-center experience of FHRMM patients (pts), defined as those with…
-
Artikel Jurnal
Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma
Abstract: Patients with relapsed/refractory (R/R) multiple myeloma (MM) are often frail with preexisting comorbidities and poor performance status (PS). To evaluate clinical characteristics and outcomes based on frailty, we conducted a single-center retrospective study of patients with R/R MM who…